Gene Therapy Lyfgenia denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Aetna Duplicate Therapy Denial for Lyfgenia — Why It Happens and How to Appeal

Lyfgenia (lovotibeglogene autotemcel) is an FDA-approved one-time gene therapy for sickle cell disease. A "duplicate therapy" denial means Aetna's system has flagged a conflict — typically because another gene therapy (often Casgevy/exagamglogene autotemcel), a stem cell transplant, or another disease-modifying treatment appears in your record. Because Lyfgenia is a one-time therapy and gene therapies for sickle cell are not interchangeable on a clinical or biological level, this denial category is highly contestable.

## Why This Denial Is Appealable

Aetna's duplicate therapy edits are designed to prevent redundant use of clinically equivalent treatments. Lyfgenia and other gene therapies are distinct biologic products with different mechanisms, vectors, and clinical profiles. They are not interchangeable. If a prior gene therapy was attempted but did not result in successful engraftment, or if the other treatment flagged is a conventional disease-modifying agent rather than a gene therapy, the duplicate-therapy logic does not apply. Your prescriber is in the best position to explain this distinction.

## Federal Appeal Framework

• Internal appeal: File within 180 days of denial. Aetna must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719): After final internal denial, you are entitled to independent external review, typically within approximately 4 months. An Independent Review Organization reviews without deference to Aetna's decision.
• ERISA §503: Employer-sponsored plans carry federally guaranteed full-and-fair review rights.
• Expedited review: Request in writing if delay poses serious risk to health.

## Documentation to Gather

1. Prescriber letter: Your treating hematologist or gene therapy specialist should explain why Lyfgenia is not duplicative of any prior or concurrent treatment — addressing the specific treatment flagged in the denial. 2. History of prior treatment(s): If another gene therapy was previously attempted, document its outcome. If it failed or was abandoned, that record directly refutes the duplicate-therapy logic. 3. Clinical distinction letter: If the flagged "duplicate" is a conventional disease-modifying agent (not a gene therapy), the prescriber should clarify the clinical difference between that treatment and a gene therapy. 4. FDA prescribing labels: Attach both the Lyfgenia label and the label for the product flagged as a duplicate, to demonstrate they are distinct products with distinct mechanisms. 5. Aetna policy language: Request the specific duplicate-therapy policy or clinical policy bulletin (CPB) Aetna applied, and identify any language that distinguishes between drug classes.

## Criteria-Mapping Structure

| Aetna Duplicate-Therapy Claim | Your Rebuttal | |---|---| | Product X already on file | Clarify whether X was actually administered, failed, or is a different drug class | | Therapies deemed clinically equivalent | FDA labels and prescriber letter demonstrating distinct mechanisms | | Overlapping treatment period | Document dates; confirm no concurrent gene therapy |

This denial often resolves at the internal appeal stage when a clear prescriber letter explains the clinical non-equivalence of the flagged products.